Seahorse Bioscience, a North Billerica-based provider of products for the biological research and drug discovery industries, has raised $9.4 million in venture capital, the company disclosed in a new filing with the Securities and Exchange Commission. Four separate investors participated in the offering.

The Seahorse Extracellular Flux (XF) Analyzer, and XF Stress Test Kits, make cellular bioenergetic studies simple, efficient and user-friendly. The first new in vitro metabolic measurement in 50 years, XF Analyzers non-invasively profile the metabolic activity of cells in minutes, offering scientists a physiologic cell based assay for determination of basal oxygen consumption, glycolysis rates, ATP turnover and respiratory capacity in a single experiment to assess mitochondrial dysfunction.

Serving the life sciences industry since 2001, Seahorse Bioscience provides industry-leading analytical instruments, biomanufacturing systems and consumable labware products for biological research and drug discovery. The firm's customers include scientists at academic institutions, pharmaceutical and biotech organizations, as well as OEM manufacturers of assay kits and lab instruments suppliers.